{"id":1322,"date":"2026-01-24T08:35:20","date_gmt":"2026-01-24T08:35:20","guid":{"rendered":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/vandetanib-100-mg-in-metastatic-hereditary-medullary-thyroid-cancer-a-phase-ii-open-label-study\/"},"modified":"2026-01-24T08:35:20","modified_gmt":"2026-01-24T08:35:20","slug":"vandetanib-100-mg-in-metastatic-hereditary-medullary-thyroid-cancer-a-phase-ii-open-label-study","status":"publish","type":"post","link":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/vandetanib-100-mg-in-metastatic-hereditary-medullary-thyroid-cancer-a-phase-ii-open-label-study\/","title":{"rendered":"VANDETANIB (100 MG) IN METASTATIC HEREDITARY MEDULLARY THYROID CANCER: A PHASE II OPEN-LABEL STUDY"},"content":{"rendered":"<div class=\"article-authors\">Robinson B.<sup>1<\/sup>, Paz-Ares L.<sup>2<\/sup>, Krebs A.<sup>3<\/sup>, Vasselli J.<sup>3<\/sup>, Haddad R.<sup>4<\/sup> <\/div>\n<div class=\"article-institutes\"><sup>1<\/sup>Kolling Institute of Medical Research, University of Sydney, Australia, <sup>2<\/sup>Doce de Octubre University Hospital, Madrid, Spain, <sup>3<\/sup>AstraZeneca, Wilmington, DE, USA, <sup>4<\/sup>Dana-Farber Cancer Institute, Boston, MA, USA<\/div>\n<div class=\"article-abstract\">\n<h2>Abstract<\/h2>\n<p><strong>Objectives:<\/strong> Vandetanib (ZACTIMA&trade;) is a once-daily oral agent that selectively targets RET, VEGFR and EGFR signalling pathways. Vandetanib 300 mg\/day has previously demonstrated antitumour activity in patients with hereditary medullary thyroid cancer (MTC). This study investigated the efficacy of vandetanib 100 mg\/day in patients with hereditary MTC (study code D4200C00068). <br \/><strong>Methods:<\/strong> Eligible patients with unresectable, measurable, locally advanced or metastatic hereditary MTC received vandetanib 100 mg. Upon disease progression, eligible patients could enter post-progression treatment with vandetanib 300 mg until a withdrawal criterion was met. The primary objective was to assess the objective tumour response rate (RECIST). <br \/><strong>Results:<\/strong> The study comprised 19 patients (13 male\/6 female; median age 45 years), including 15 (79%) who had a confirmed RET germline mutation. As of 18 December 2007, 14 patients continued to receive vandetanib 100 mg, two patients had entered post-progression treatment with vandetanib 300 mg, and three patients had discontinued treatment (1 due to an adverse event, 1 withdrawal of consent, 1 death). Preliminary objective tumour assessments have demonstrated partial responses in two patients, stable disease &ge;24 weeks in six patients and progressive disease in two patients, yielding an objective response rate of 10.5% (2\/19) and a disease control rate of 42% (8\/19). <br \/><strong>Conclusions:<\/strong> These preliminary results suggest that vandetanib 100 mg also has activity in patients with hereditary MTC. This study has completed accrual and a final analysis will be performed in April 2008. ZACTIMA is a trademark of the AstraZeneca group of companies. <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Robinson B.1, Paz-Ares L.2, Krebs A.3, Vasselli J.3, Haddad R.4 1Kolling Institute of Medical Research, University of Sydney, Australia, 2Doce de Octubre University Hospital, Madrid, Spain, 3AstraZeneca, Wilmington, DE, USA, 4Dana-Farber Cancer Institute, Boston, MA, USA Abstract Objectives: Vandetanib (ZACTIMA&trade;) is a once-daily oral agent that selectively targets RET, VEGFR and EGFR signalling pathways. Vandetanib <a class=\"read-more\" href=\"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/2026\/01\/24\/vandetanib-100-mg-in-metastatic-hereditary-medullary-thyroid-cancer-a-phase-ii-open-label-study\/\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45,2,9],"tags":[],"class_list":["post-1322","post","type-post","status-publish","format-standard","hentry","category-volume-7-issue-3","category-journal-articles","category-volume-7"],"_links":{"self":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/1322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/comments?post=1322"}],"version-history":[{"count":0,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/1322\/revisions"}],"wp:attachment":[{"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/media?parent=1322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/categories?post=1322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peaceful-mccarthy.213-158-90-25.plesk.page\/index.php\/wp-json\/wp\/v2\/tags?post=1322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}